Immunomatics

AI to reduce transplant rejection and save lives.

https://wefunder.com/immunomatics

Total raised on Wefunder: 0

Total investors: 0

Quick facts

  • Founded by a stem cell transplant survivor with training in computational biology and AI
  • Awarded a $207,740 NIH Phase I SBIR grant, non-dilutive capital, & third-party scientific validation
  • Tackling a major unmet need: roughly 1 in 5 kidney transplants fail within five years
  • AI rejection-risk scoring designed to work with data already collected in pre-transplant workflows
  • Collaboration with UC San Diego's Immunogenetics & Transplantation Lab; access to SRTR data

Team profiles

Immunomatics

AI to reduce transplant rejection and save lives

FIRST GOAL HIT

$58,660

reserved by 41 investors
INVESTMENT TERMS
Future Equity
$8M valuation cap

Highlights

1
Founded by a stem cell transplant survivor with training in computational biology and AI
2
Awarded a $207,740 NIH Phase I SBIR grant, non-dilutive capital, & third-party scientific validation
3
Tackling a major unmet need: roughly 1 in 5 kidney transplants fail within five years
4
AI rejection-risk scoring designed to work with data already collected in pre-transplant workflows

Team

The Problem - Too Many Failed Transplants

The deeper issue is how donors are selected. Today’s practice counts HLA mismatches and treats them as equally risky, even though evidence shows that some mismatches are well tolerated while others drive rejection. Clinicians lack a reliable tool to tell the difference, so one of the most consequential decisions in medicine is made with a blunt instrument.

A note from our founder

The Solution - Better Matches, Better Outcomes

Immunomatics is developing AI software that goes beyond counting mismatches, estimating the relative rejection risk of specific donor-recipient incompatibilities before transplantation. Our platform analyzes donor and patient genetic data to produce a rejection-risk score designed to help transplant teams select safer donors, personalize immunosuppression to each patient’s risk, and monitor for rejection more effectively.

A rejection-risk score clinicians can act on

The approach is built to fit the clinic, not replace it. Risk analysis uses existing transplant workflow data.

Traction & credibility

Beyond the grant, the team is advancing discussions with transplant centers and building the data partnerships needed to validate the model against real-world outcomes. The NIH award is a meaningful external signal: independent reviewers judged both the science and the team worth funding.

Market opportunity

Reasons to invest

As with any early-stage healthcare company, this opportunity is subject to scientific, execution, regulatory, and commercialization risks.

Roadmap

The ask & use of funds

Immunomatics intends to raise $500,000 in this offering as a Simple Agreement for Future Equity (SAFE), with a 20% discount and $8M post-money valuation cap. The proceeds will advance the platform through proof of concept and early clinical validation, allocated across four strategic areas:

FAQ

Overview